Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2012
A phase II pilot trial incorporating bevacizumab into dose-dense doxorubicin and cyclophosphamide followed by paclitaxel in patients with lymph node positive breast cancer: a trial coordinated by the Eastern Cooperative Oncology Group.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node-Positive and High-Risk Lymph Node-Negative Breast Cancer (E5103).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018Trial
- Effect of Unblinding on Participants' Perceptions of Risk and Confidence in a Large Double-Blind Clinical Trial of Chemotherapy for Breast Cancer.JAMA oncology · 2015Trial
- A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2011Trial
- Inflammatory breast cancer, best practice in the community setting.NPJ breast cancer · 2025Review
- TRPML1 as a potential therapeutic target for triple-negative breast cancer: a review.Frontiers in oncology · 2023Review
- The Landscape of Targeted Therapies in TNBC.Cancers · 2020Review
- Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08-10 trial.Therapeutic advances in medical oncology · 2019Article
- Cardiac effects of anticancer therapy in the elderly.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2014Review
- The potential role of aerobic exercise to modulate cardiotoxicity of molecularly targeted cancer therapeutics.The oncologist · 2013Review
- Targeted therapies in breast cancer: are heart and vessels also being targeted?Breast cancer research : BCR · 2012Review
- Chemotherapy-resistant metastatic breast cancer.Current treatment options in oncology · 2012Article
- Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial.Leukemia & lymphoma · 2012Article
- Review
- Bevacizumab in the treatment of patients with advanced breast cancer: where have we landed?Therapeutic advances in medical oncology · 2010Article
- Anti-angiogenesis therapies: their potential in cancer management.OncoTargets and therapy · 2010Article
- Antiangiogenic therapy for breast cancer.Breast cancer research : BCR · 2010Review
- Antiangiogenic therapies in early-stage breast cancer.Clinical breast cancer · 2010Review
- Targeting signal transduction pathways in metastatic breast cancer: a comprehensive review.The oncologist · 2010Review
- Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2009Article
- Adverse effects of anticancer agents that target the VEGF pathway.Nature reviews. Clinical oncology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundE2104 was designed to evaluate the safety of two different strategies incorporating bevacizumab into anthracycline-containing adjuvant therapy as a precursor to a definitive randomized phase III trial. PATIENTS AND
methodsPatients were sequentially assigned to one of two treatment arms. In addition to dose-dense doxorubicin and cyclophosphamide followed by paclitaxel (Taxol) (ddAC→T), all patients received bevacizumab (10 mg/kg every 2 weeks × 26) initiated either concurrently with AC (Arm A: ddBAC→BT→B) or with paclitaxel (Arm B: ddAC→BT→B). The primary end point was incidence of clinically apparent cardiac dysfunction (CHF).
resultsPatients enrolled were 226 in number (Arm A 104, Arm B 122). Grade 3 hypertension, thrombosis, proteinuria and hemorrhage were reported for 12, 2, 2 and <1% of patients, respectively. Two patients developed grade 3 or more cerebrovascular ischemia. Three patients in each arm developed CHF. There was no significant difference between arms in the proportion of patients with an absolute decrease in left ventricular ejection fraction of >15% or >10% to below the lower limit of normal post AC or post bevacizumab.
conclusionsIncorporation of bevacizumab into anthracycline-containing adjuvant therapy does not result in prohibitive cardiac toxicity. The definitive phase III trial (E5103) was activated with systematic and extensive cardiac monitoring to define the true impact of bevacizumab on cardiac function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.